Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani. Dear Fellow Shareholders: Clearmind’s overarching mission since inception has been to promptly…

Source

Previous articlePsychedelics Weekly – Proposition 122 in Action, The Economics of Psychedelics, and Could States Legalize by 2037?
Next articleThe atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital